Audio Interview

Using real-world insights on drug interactions to inform drug development

Published on July 31, 2025   14 min

A selection of talks on Pharmaceutical Sciences

Please wait while the transcript is being prepared...
0:00
Interviewer: We're joined today by Amita Datta-Mannan, Associate Vice President at Eli Lilly, to discuss a recent paper with colleagues which used real world data on drug-drug interactions in psoriasis patients to inform decision-making during the early stages of developing a new psoriasis drug. Amita, thank you very much for joining us today. Dr. Datta-Mannan: Thank you for the opportunity to discuss some of this work and share with other colleagues. Interviewer: Can you start by providing a brief description of the study? I.e., what was the need you saw to address? How did you and your team approach it, and what were your key findings? Dr. Datta-Mannan: Yes, of course. Thank you again for this opportunity. Really, the focus of our study was on polypharmacy, or in other words, the use of multiple concomitant medications and how these may interact with each other to impact the safety and effectiveness of a drug and thereby, the patient experience. In this particular study, we were really interested in studying polypharmacy in psoriasis. As many may know, psoriasis is really this particularly bothersome and relatively high-incidence skin disease that really manifests as a rash with these very itchy, scaly red patches all over the body. While some may think this disease is not life-threatening as some cancers, for patients with severe psoriasis, the disorder can be very detrimental in multiple ways. Interferes with sleep, makes it difficult to concentrate, affects appearance, self confidence, and leads to depression, and other psychological disorders. It's also linked to other physical diseases such

Quiz available with full talk access. Request Free Trial or Login.

Hide

Using real-world insights on drug interactions to inform drug development

Embed in course/own notes